LPTX

• Clinical-stage pharma company developing first-in-class antibodies for treating cancer
  • Lead asset DKN-01= has Orphan Drug Designation and is in P2 of development for multiple types of cancer
• Has an exclusive option and license agreement for DKN-01 with Bigene (BGNE)
  • Received $3M upfront and is eligible for a total of $132m in developmental and commercial milestones as well as equity investment
• Testing DKN-01 in combination with other anti-cancer drugs, most notably Roche’s (RHHBY) and Bristol-Myer-Squibb’s (BMY) immunotherapies (Tecentriq and Opdivo, respectively)

• Entered an exclusive license agreement with BGNE for the rights to develop/commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand; 1/3/20 
• Dosed the first patient in the P2 study of DKN-01, in combo with BGNE’s anti-PD-1 antibody in patients with gastric or gastroesophageal junction cancer (G/GEJ); 9/21/20
• DKN-01 was awarded Fast Track Designation for treating gastric and G/GEJ cancer; 9/24/20
• Data regarding  DKN-01’s mechanism of action was published in Molecular Cancer Research; 12/22/20

• Presented P2 data at a medical conference (Society of Gynecologic Oncology); 3/22/21
  • Objective responses were maintained over 2-years
• Completed enrollment for a P2 study of DKN-01+ tislelizumab (with or without chemotherapy) as first-line or second-line therapy in inoperable/advanced G/GEJ cancer; 4/1/21
• Announced a partnership with Flagship Biosciences; 4/12/21
  • The duo shared a poster at a medical conference (AACR) in April highlighting their research
  • Expanded the partnership to develop an image analysis RNAscope® assay
• Highlights from 1Q21 earnings; 5/14/21:
  • Nearing a significant milestone in its partnership with Bigene
  • Presented DKK1 biomarker assay validation data
  • OK financials with $54M in cash and a burn for the quarter of ~$9M

Coming soon